Invention Application
- Patent Title: NOVEL ANTIBODIES AND COMBINED USE OF A TREG DEPLETING ANTIBODY AND AN IMMUNOSTIMULATORY ANTIBODY
-
Application No.: US17819234Application Date: 2022-08-11
-
Publication No.: US20230058227A1Publication Date: 2023-02-23
- Inventor: Björn FRENDÉUS , Linda MÅRTENSSON , Monika SEMMRICH , Ingrid TEIGE , Stephen BEERS , Aymen AL-SHAMKHANI , Juliet GRAY , Martin GLENNIE
- Applicant: BIOINVENT INTERNATIONAL AB , CANCER RESEARCH TECHNOLOGY LIMITED
- Applicant Address: SE Lund; GB London
- Assignee: BIOINVENT INTERNATIONAL AB,CANCER RESEARCH TECHNOLOGY LIMITED
- Current Assignee: BIOINVENT INTERNATIONAL AB,CANCER RESEARCH TECHNOLOGY LIMITED
- Current Assignee Address: SE Lund; GB London
- Priority: GB1712032.0 20170726
- Main IPC: C07K16/28
- IPC: C07K16/28
Abstract:
Described is the sequential administration of first a Treg depleting antibody mole-cute selected from antibody molecules, such as an antibody molecule binding specifically to target belonging to the tumour necrosis factor receptor superfamily (TNFRSF), such as a Treg depleting anti-4-1 BB antibody or a Treg depleting OX-40 antibody, and then an immunostimulatory antibody molecule, such as an immunostimulatory anti-4-1 BB anti-body or an immunostimulatory OX-40 antibody, for use in the treatment of cancer. De-scribed are also novel anti-4-1 BB antibodies and novel OX-40 antibodies that may be used in such sequential administration.
Information query
